PHLAX Rating, Research - Prudential Jennison Health Sciences A

Prudential Jennison Health Sciences A (phlax)

Last Updated by WikiWealth | Update This Page Now

►Summary | Add New Mutual Fund | Feedback

Short Term Rating Stock Ratings Help
placeholder_summary.png

Asset Allocation (% of Port)

US Stocks
Non-US Stocks
Bonds
Cash
Other
%
%
%
%
%

Geographic Allocation (% of Port)

North America
Europe
Asia
South America
Africa
Australia + Pacific Islands
Long Term Rating Stock Ratings Help

HOLD

SWOT Statistics

Strengths + Opportunities = 23

Threats + Weaknesses = 19

When strengths & opportunities substantially exceed threats & weaknesses an investment in the phlax mutual fund has great long term potential.

Fund Management Team

Fund Description Update

Prudential Jennison Health Sciences A (PHLAX) Description: PHLAX is a mutual fund, which is an investment that owns a basket of assets. The PHLAX mutual fund was provided by Prudential and this investment vehicle derives the majority of its value from equity holdings (stocks). Prudentials mutual fund has a long management tenure and is in the average fund size classification. PHLAXs minimum initial investment amount is $2500 while the IRA minimum is $1000. PHLAXs expense ratio is roughly 1%. The latest PHLAXs front end load was 6% and the back end load was 0%. The Prudential Jennison Health Sciences A (PHLAX) mutual fund falls under the health category. PHLAX focuses its investments in USA and PHLAX is focused on the health industry or fund sector. The Prudential Jennison Health Sciences A (PHLAX) mutual fund is not a leveraged fund and it does not have inverse fund properties. An investor can find PHLAXs top holdings, fundamental analysis, ratings, and fund risk (volatility) on the left side of the screen. The right side of PHLAXs research report features technical analysis and long term investment potential.

Portfolio Strategy Update

This investment vehicle seeks long-term capital appreciation. The fund normally invests at least 80% of investable assets in equity and equity-related securities of companies in the health sciences sector. It principally buys securities of companies in the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and HMOs that derive a substantial portion of their sales from healthcare-related products or services. The funds non-diversified.


Management Analysis Update


Performance Analysis Update